Related Experiment Videos
Injectable microspheres with controlled drug release for glaucoma filtering surgery.
H Kimura1, Y Ogura, T Moritera
1Department of Ophthalmology, Faculty of Medicine, Kyoto University, Japan.
Investigative Ophthalmology & Visual Science
|November 1, 1992
Summary
Biodegradable microspheres releasing adriamycin (ADR) effectively reduced post-surgical fibrosis and maintained filtering bleb patency in glaucoma surgery models. Lower ADR doses showed fewer corneal complications, suggesting a promising approach for preventing ocular fibrosis.
Area of Science:
- Ophthalmology
- Biomaterials Science
- Pharmacology
Background:
- Post-surgical fibrosis is a common complication after glaucoma filtering surgery, potentially leading to bleb failure.
- Controlled drug delivery systems aim to improve therapeutic outcomes and minimize side effects.
Purpose of the Study:
- To evaluate the efficacy of biodegradable poly(lactic acid) microspheres for controlled release of adriamycin (ADR) in preventing post-surgical fibrosis.
- To assess the impact of ADR-loaded microspheres on intraocular pressure and filtering bleb patency.
Main Methods:
- A rabbit model of glaucoma filtering surgery (posterior lip sclerotomy) was used.
- Subconjunctival injections of adriamycin (ADR)-loaded microspheres (100 or 200 micrograms) or control microspheres were administered immediately post-surgery.
- Intraocular pressure, filtering bleb patency, and corneal complications were monitored.
Main Results:
- ADR-loaded microspheres significantly reduced intraocular pressure and prolonged filtering bleb patency compared to controls.
- The 100 microgram ADR dose showed no corneal complications, while the 200 microgram dose caused transient peripheral corneal opacities and epithelial erosion.
- Corneal issues resolved within 4 weeks in the higher dose group.
Conclusions:
- Controlled release of adriamycin via biodegradable microspheres is a promising strategy for preventing fibrosis after glaucoma surgery.
- Optimizing ADR dosage is crucial to balance antifibrotic efficacy with ocular surface safety.